vs
McEwen Inc.（MUX）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是McEwen Inc.的2.0倍（$127.1M vs $64.6M），McEwen Inc.同比增速更快（92.8% vs 17.1%），过去两年McEwen Inc.的营收复合增速更高（25.2% vs 20.8%）
McEwen Inc（股票代码MUX）是一家自然资源企业，主要从事金、银、铜矿产的勘探、开发与生产业务，运营项目分布于南北美洲，秉持可持续负责任的采矿准则，产品面向全球大宗商品市场供应。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
MUX vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的2.0倍
$64.6M
营收增速更快
MUX
高出75.7%
17.1%
两年增速更快
MUX
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.6M | $127.1M |
| 净利润 | $38.1M | — |
| 毛利率 | 26.9% | 51.0% |
| 营业利润率 | 34.2% | -54.6% |
| 净利率 | 59.0% | — |
| 营收同比 | 92.8% | 17.1% |
| 净利润同比 | 563.1% | — |
| 每股收益（稀释后） | $0.66 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MUXZLAB
| Q4 25 | $64.6M | $127.1M | ||
| Q3 25 | $50.5M | $115.4M | ||
| Q2 25 | $46.7M | $109.1M | ||
| Q1 25 | $35.7M | $105.7M | ||
| Q4 24 | $33.5M | $108.5M | ||
| Q3 24 | $52.3M | $101.8M | ||
| Q2 24 | $47.5M | $100.1M | ||
| Q1 24 | $41.2M | $87.1M |
净利润MUXZLAB
| Q4 25 | $38.1M | — | ||
| Q3 25 | $-462.0K | $-36.0M | ||
| Q2 25 | $3.0M | $-40.7M | ||
| Q1 25 | $-6.3M | $-48.4M | ||
| Q4 24 | $-8.2M | — | ||
| Q3 24 | $-2.1M | $-41.7M | ||
| Q2 24 | $-13.0M | $-80.3M | ||
| Q1 24 | $-20.4M | $-53.5M |
毛利率MUXZLAB
| Q4 25 | 26.9% | 51.0% | ||
| Q3 25 | 15.5% | 59.5% | ||
| Q2 25 | 26.3% | 60.6% | ||
| Q1 25 | 28.2% | 63.6% | ||
| Q4 24 | 1.1% | 61.5% | ||
| Q3 24 | 26.4% | 64.1% | ||
| Q2 24 | 22.7% | 64.9% | ||
| Q1 24 | 14.6% | 61.4% |
营业利润率MUXZLAB
| Q4 25 | 34.2% | -54.6% | ||
| Q3 25 | -16.7% | -42.3% | ||
| Q2 25 | -7.2% | -50.3% | ||
| Q1 25 | -21.4% | -53.3% | ||
| Q4 24 | -43.4% | -62.6% | ||
| Q3 24 | -0.2% | -66.6% | ||
| Q2 24 | -29.4% | -76.0% | ||
| Q1 24 | -53.3% | -80.7% |
净利率MUXZLAB
| Q4 25 | 59.0% | — | ||
| Q3 25 | -0.9% | -31.2% | ||
| Q2 25 | 6.5% | -37.3% | ||
| Q1 25 | -17.6% | -45.8% | ||
| Q4 24 | -24.6% | — | ||
| Q3 24 | -4.0% | -40.9% | ||
| Q2 24 | -27.4% | -80.2% | ||
| Q1 24 | -49.4% | -61.4% |
每股收益（稀释后）MUXZLAB
| Q4 25 | $0.66 | $-0.05 | ||
| Q3 25 | $-0.01 | $-0.03 | ||
| Q2 25 | $0.06 | $-0.04 | ||
| Q1 25 | $-0.12 | $-0.04 | ||
| Q4 24 | $-0.15 | $-0.09 | ||
| Q3 24 | $-0.04 | $-0.04 | ||
| Q2 24 | $-0.26 | $-0.08 | ||
| Q1 24 | $-0.41 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $72.1M | $689.6M |
| 总债务越低越好 | $126.2M | — |
| 股东权益账面价值 | $546.2M | $715.5M |
| 总资产 | $820.2M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.23× | — |
8季度趋势，按日历期对齐
现金及短期投资MUXZLAB
| Q4 25 | $72.1M | $689.6M | ||
| Q3 25 | $75.4M | $717.2M | ||
| Q2 25 | $69.5M | $732.2M | ||
| Q1 25 | $79.3M | $757.3M | ||
| Q4 24 | $15.3M | $779.7M | ||
| Q3 24 | $30.2M | $616.1M | ||
| Q2 24 | $42.6M | $630.0M | ||
| Q1 24 | $22.0M | $650.8M |
总债务MUXZLAB
| Q4 25 | $126.2M | — | ||
| Q3 25 | $126.0M | — | ||
| Q2 25 | $125.8M | — | ||
| Q1 25 | $125.5M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $31.0M | — | ||
| Q2 24 | $34.0M | — | ||
| Q1 24 | $37.0M | — |
股东权益MUXZLAB
| Q4 25 | $546.2M | $715.5M | ||
| Q3 25 | $488.6M | $759.9M | ||
| Q2 25 | $484.5M | $791.7M | ||
| Q1 25 | $479.8M | $810.8M | ||
| Q4 24 | $495.0M | $840.9M | ||
| Q3 24 | $502.1M | $667.7M | ||
| Q2 24 | $485.2M | $704.2M | ||
| Q1 24 | $482.5M | $762.2M |
总资产MUXZLAB
| Q4 25 | $820.2M | $1.2B | ||
| Q3 25 | $747.6M | $1.2B | ||
| Q2 25 | $735.6M | $1.2B | ||
| Q1 25 | $730.6M | $1.2B | ||
| Q4 24 | $664.6M | $1.2B | ||
| Q3 24 | $667.8M | $985.3M | ||
| Q2 24 | $645.1M | $987.4M | ||
| Q1 24 | $638.7M | $988.4M |
负债/权益比MUXZLAB
| Q4 25 | 0.23× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | 0.26× | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.08× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 0.08× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流MUXZLAB
| Q4 25 | $3.1M | $-26.0M | ||
| Q3 25 | $5.2M | $-32.0M | ||
| Q2 25 | $478.0K | $-31.0M | ||
| Q1 25 | $-1.9M | $-61.7M | ||
| Q4 24 | $-1.2M | $-55.8M | ||
| Q3 24 | $23.2M | $-26.8M | ||
| Q2 24 | $3.6M | $-42.2M | ||
| Q1 24 | $3.9M | $-90.1M |
自由现金流MUXZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率MUXZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度MUXZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率MUXZLAB
| Q4 25 | 0.08× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MUX
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
